Expert Insights

Peter Galle, MD, PhD, discussed results from the CheckMate 9DW trial which identified nivolumab plus ipilimumab as a potential new first-line option for patients with previously untreated, unresectable hepatocellular carcinoma.

Andrea Cercek, MD, discussed results from a phase 2 study which demonstrated durable recurrence-free with neoadjuvant dostarlimab among patients with locally advanced mismatch repair deficient rectal cancer.

Efrat Dotan, MD, discussed results from the phase 2 GIANT study which compared gemcitabine and nab-paclitaxel to 5-fluorouracil, leucovorin, and liposomal irinotecan among older adults with treatment-naive metastatic pancreatic cancer.

Matthew Matasar, MD, shares expert insights into the current and evolving “potentially practice-changing” clinical trial research landscape for the treatment of patients with diffuse large B-cell lymphoma.

At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...

Aaron Gerds, MD, discusses data from the MANIFEST-2 and TRANSFORM-1 trials exploring first-line treatment options for patients with myelofibrosis, as well as analyzes the establishment of optimal clinical trial end points.

Aaron Gerds, MD, presents insights into data from a study in which luspatercept improved anemia and transfusion burden for patients with myelofibrosis, and explains next steps for investigating luspatercept in further clinical trials.

Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...